<?xml version='1.0' encoding='utf-8'?>
<document id="26387027"><sentence text="Evaluation of potential pharmacokinetic drug-drug interaction between armodafinil and risperidone in healthy adults."><entity charOffset="70-81" id="DDI-PubMed.26387027.s1.e0" text="armodafinil" /><entity charOffset="86-97" id="DDI-PubMed.26387027.s1.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.26387027.s1.e0" e2="DDI-PubMed.26387027.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26387027.s1.e0" e2="DDI-PubMed.26387027.s1.e1" /></sentence><sentence text="Patients with bipolar I disorder and schizophrenia have an increased risk of obstructive sleep apnea" /><sentence text=" The effects of armodafinil, a weak cytochrome P450 (CYP) 3A4 inducer, on pharmacokinetics and safety of risperidone, an atypical antipsychotic used to treat major psychiatric illness, were investigated"><entity charOffset="16-27" id="DDI-PubMed.26387027.s3.e0" text="armodafinil" /><entity charOffset="105-116" id="DDI-PubMed.26387027.s3.e1" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.26387027.s3.e0" e2="DDI-PubMed.26387027.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26387027.s3.e0" e2="DDI-PubMed.26387027.s3.e1" /></sentence><sentence text="" /><sentence text="Healthy subjects received 2 mg risperidone alone and after armodafinil pretreatment (titrated to 250 mg/day)"><entity charOffset="31-42" id="DDI-PubMed.26387027.s5.e0" text="risperidone" /><entity charOffset="59-70" id="DDI-PubMed.26387027.s5.e1" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.26387027.s5.e0" e2="DDI-PubMed.26387027.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26387027.s5.e0" e2="DDI-PubMed.26387027.s5.e1" /></sentence><sentence text=" Pharmacokinetic parameters were derived from plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone (formed via CYP2D6 and CYP3A4), collected before and over 4 days after risperidone administration, and from steady-state plasma concentrations of armodafinil and its circulating metabolites, R-modafinil acid and modafinil sulfone"><entity charOffset="71-82" id="DDI-PubMed.26387027.s6.e0" text="risperidone" /><entity charOffset="110-130" id="DDI-PubMed.26387027.s6.e1" text="9-hydroxyrisperidone" /><entity charOffset="202-213" id="DDI-PubMed.26387027.s6.e2" text="risperidone" /><entity charOffset="277-288" id="DDI-PubMed.26387027.s6.e3" text="armodafinil" /><entity charOffset="322-338" id="DDI-PubMed.26387027.s6.e4" text="R-modafinil acid" /><entity charOffset="343-360" id="DDI-PubMed.26387027.s6.e5" text="modafinil sulfone" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e0" e2="DDI-PubMed.26387027.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e0" e2="DDI-PubMed.26387027.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e0" e2="DDI-PubMed.26387027.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e0" e2="DDI-PubMed.26387027.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e0" e2="DDI-PubMed.26387027.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e0" e2="DDI-PubMed.26387027.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e1" e2="DDI-PubMed.26387027.s6.e1" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e1" e2="DDI-PubMed.26387027.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e1" e2="DDI-PubMed.26387027.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e1" e2="DDI-PubMed.26387027.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e1" e2="DDI-PubMed.26387027.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e2" e2="DDI-PubMed.26387027.s6.e2" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e2" e2="DDI-PubMed.26387027.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e2" e2="DDI-PubMed.26387027.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e2" e2="DDI-PubMed.26387027.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e3" e2="DDI-PubMed.26387027.s6.e3" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e3" e2="DDI-PubMed.26387027.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e3" e2="DDI-PubMed.26387027.s6.e5" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e4" e2="DDI-PubMed.26387027.s6.e4" /><pair ddi="false" e1="DDI-PubMed.26387027.s6.e4" e2="DDI-PubMed.26387027.s6.e5" /></sentence><sentence text=" Safety and tolerability were assessed" /><sentence text="" /><sentence text="Thirty-six subjects receiving study drug were evaluable for safety; 34 were evaluable for pharmacokinetics" /><sentence text=" Risperidone maximum plasma concentration (C max) decreased from mean 16"><entity charOffset="1-12" id="DDI-PubMed.26387027.s10.e0" text="Risperidone" /></sentence><sentence text="5 ng/mL when given alone to 9" /><sentence text="2 ng/mL after armodafinil pretreatment (geometric mean ratio [90 % CI] 0"><entity charOffset="14-25" id="DDI-PubMed.26387027.s12.e0" text="armodafinil" /></sentence><sentence text="55 [0" /><sentence text="50-0" /><sentence text="61]); area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) decreased from 92" /><sentence text="3 to 44" /><sentence text="5 ng·h/mL (geometric mean ratio [90 % CI] 0" /><sentence text="51 [0" /><sentence text="46-0" /><sentence text="55])" /><sentence text=" C max and AUC0-∞ for 9-hydroxyrisperidone were also reduced (geometric mean ratios [90 % CI] 0"><entity charOffset="22-42" id="DDI-PubMed.26387027.s21.e0" text="9-hydroxyrisperidone" /></sentence><sentence text="81 [0" /><sentence text="77-0" /><sentence text="85] and 0" /><sentence text="73 [0" /><sentence text="69-0" /><sentence text="77], respectively)" /><sentence text=" Adverse events were consistent with known safety profiles" /><sentence text="" /><sentence text="Consistent with CYP3A4 induction, risperidone and 9-hydroxyrisperidone systemic exposure was reduced in the presence of armodafinil"><entity charOffset="34-45" id="DDI-PubMed.26387027.s30.e0" text="risperidone" /><entity charOffset="50-70" id="DDI-PubMed.26387027.s30.e1" text="9-hydroxyrisperidone" /><entity charOffset="120-131" id="DDI-PubMed.26387027.s30.e2" text="armodafinil" /><pair ddi="false" e1="DDI-PubMed.26387027.s30.e0" e2="DDI-PubMed.26387027.s30.e0" /><pair ddi="false" e1="DDI-PubMed.26387027.s30.e0" e2="DDI-PubMed.26387027.s30.e1" /><pair ddi="false" e1="DDI-PubMed.26387027.s30.e0" e2="DDI-PubMed.26387027.s30.e2" /><pair ddi="false" e1="DDI-PubMed.26387027.s30.e1" e2="DDI-PubMed.26387027.s30.e1" /><pair ddi="false" e1="DDI-PubMed.26387027.s30.e1" e2="DDI-PubMed.26387027.s30.e2" /></sentence><sentence text=" Concomitant armodafinil and risperidone use may necessitate risperidone dosage adjustment, particularly when starting or stopping coadministration of the two drugs"><entity charOffset="13-24" id="DDI-PubMed.26387027.s31.e0" text="armodafinil" /><entity charOffset="29-40" id="DDI-PubMed.26387027.s31.e1" text="risperidone" /><entity charOffset="61-72" id="DDI-PubMed.26387027.s31.e2" text="risperidone" /><pair ddi="false" e1="DDI-PubMed.26387027.s31.e0" e2="DDI-PubMed.26387027.s31.e0" /><pair ddi="false" e1="DDI-PubMed.26387027.s31.e0" e2="DDI-PubMed.26387027.s31.e1" /><pair ddi="false" e1="DDI-PubMed.26387027.s31.e0" e2="DDI-PubMed.26387027.s31.e2" /><pair ddi="false" e1="DDI-PubMed.26387027.s31.e1" e2="DDI-PubMed.26387027.s31.e1" /><pair ddi="false" e1="DDI-PubMed.26387027.s31.e1" e2="DDI-PubMed.26387027.s31.e2" /></sentence><sentence text=" However, any such decision should be based on patient disease state and clinical status" /><sentence text="" /></document>